文献速递免疫规划传染病防控与疫情报告

福建省2012—2017年疑似预防接种相关死亡病例特征分析

[Analysis on the characteristics of suspected vaccine-related deaths in Fujian Province, 2012-2017].
PubMed 文献 · Zhonghua Yu Fang Yi Xue Za Zhi · 2019-01-01

该研究基于中国AEFI监测系统与福建省免疫规划信息系统,分析2012—2017年福建省33例疑似预防接种相关死亡病例。结果显示8例为预防接种异常反应,25例为偶合症;AEFI发生率与异常反应发生率相关,但两者均与死亡率无相关性,偶合症是疑似预防接种相关死亡的主要原因。

要点

  • 疑似预防接种相关死亡以偶合症为主,33例中25例为偶合症。
  • AEFI发生率与异常反应发生率相关(r=0.64,P=0.048)。
  • AEFI及异常反应发生率与死亡率均无相关性。

核心结论

  • AEFI发生率和异常反应发生率均与疑似预防接种相关死亡率无相关性。
  • 疑似预防接种相关死亡的主要原因为偶合症。

研究设计与样本

  • 从中国AEFI监测信息管理系统提取福建省2012—2017年疑似与预防接种有关的死亡病例共33例。
  • 收集尸检报告及AEFI调查诊断专家委员会结论,并通过福建省免疫规划信息系统获取接种数据。

主要发现

  • 33例死亡病例年龄范围为26 d至52月龄,男性23例,8例为预防接种异常反应,25例为偶合症。
  • 2012—2017年分别报告2、3、6、8、7和7例。
  • AEFI发生率最高为MR疫苗38.88/10万剂(95%CI:36.85~40.91/10万剂),最低为tOPV 2.01/10万剂(95%CI:1.73~2.30/10万剂)。
  • 异常反应发生率最高为MR疫苗15.04/10万剂(95%CI:13.78~16.30/10万剂),最低为tOPV 0.38/10万剂(95%CI:0.25~0.50/10万剂)。
  • 死亡率最高为IPV 0.26/10万剂(95%CI:0.04~0.54/10万剂),最低为MMR 0.01/10万剂(95%CI:0.00~0.08/10万剂)。

关键数值与推荐

  • Spearman秩相关分析显示AEFI发生率与异常反应发生率相关(r=0.64,P=0.048)。
  • AEFI发生率与死亡率无相关性(r=-0.34,P=0.329)。
  • 异常反应发生率与死亡率无相关性(r=-0.25,P=0.484)。

临床怎么用

  • 在预防接种异常反应监测与死亡病例调查中,应重视偶合症的鉴别与专家诊断结论。
  • AEFI或异常反应发生率高低不宜直接作为死亡风险信号,应结合个案调查与尸检结果综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the characterisitics of the death cases suspected to be related to vaccination in Fujian Province from 2012 to 2017. Methods: A total of 33 death cases information which was suspected to be related to the vaccinations from 2012 to 2017 were extracted from Chinese Adverse Events Following Immunization Information System (AEFI). The autopsy reports and the conclusions made by AEFI investigation diagnosis expert committee were collected at the same time. The inoculation data were obtained through the Fujian province Immunization Program Information System. The AEFI incidence, rare vaccine reaction incidences and mortality rates following immunization were figured out to analyze the characterisitics of the death cases associated with vaccination. Results: The age of deuths cases was from 26 days to 52 months. Among 33 cases, 23 were males, and 8 were due to vaccine-related reaction, and the others were due to coincidental events. The number of rare vaccine reaction cases from 2012 to 2017 were 2,3,6,8,7 and 7, respectively. The highest AEFI incidence was measles and rubella combined attenuated live vaccine [38.88 (95%CI: 36.85-40.91)/100 000 dose], and the lowest was trivalent oral poliomyelitis attenuated live vaccine [2.01 (95%CI: 1.73-2.30)/100 000 dose]. The highest rare vaccine reaction incidence was measles and rubella combined attenuated live vaccine [15.04 (95%CI: 13.78-16.30)/100 000 dose], and the lowest was trivalent oral poliomyelitis attenuated live vaccine [0.38 (95%CI: 0.25-0.50)/100 000]. The highest mortality rate was inactivated poliomyelitis vaccine [0.26 (95%CI: 0.04-0.54)/100 000 doses], and the lowest mortality rate was measles, mumps and rubella combined attenuated live vaccine [0.01 (95%CI: 0.00-0.08)/100 000 doses]. The Spearman correlation analysis showed that there were correlations between AEFI incidence and rare vaccine reaction incidence (r=0.64, P=0.048), there were no correlations between AEFI incidence and mortality rate (r=-0.34, P=0.329), and there were no correlations between rare vaccine reaction incidence and mortality rate (r=-0.25, P=0.484). Conclusion: Neither AEFI incidence nor rare vaccine reaction incidence was correlation with mortality rate. The main causes of death following vaccination were coincidental events. 目的: 分析2012—2017年福建省疑似与预防接种有关的死亡病例特征。 方法: 收集中国疑似预防接种异常反应(AEFI)监测信息管理系统中,福建省2012—2017年疑似与预防接种有关的死亡病例个案、尸检报告以及AEFI调查诊断专家组的结论,共33例。通过福建省免疫规划信息系统收集福建省其间不同疫苗的预防接种数据,计算AEFI、异常反应发生率及死亡率,并分析福建省疑似与预防接种有关的死亡病例特征。 结果: 年龄范围为26 d至52月龄,其中8例为预防接种异常反应,25例为偶合症;2012—2017年分别报告2、3、6、8、7和7例;男性为23例(70%)。接种麻疹-风疹联合减毒活(MR)疫苗病例AEFI发生率最高,为38.88/10万剂(95%CI:36.85/10万剂~40.91/10万剂),三价口服脊髓灰质炎减毒活疫苗(tOPV)最低,为2.01/10万剂(95%CI:1.73/10万剂~2.30/10万剂);接种MR疫苗病例异常反应报告发生率最高,为15.04/10万剂(95%CI:13.78/10万剂~16.30/10万剂),tOPV最低,为0.38/10万剂(95%CI:0.25/10万剂~0.50/10万剂);接种灭活脊髓灰质炎疫苗(IPV)病例死亡率最高,为0.26/10万剂(95%CI:0.04/10万剂~0.54/10万剂),麻疹-流腮-风疹联合减毒活疫苗最低,为0.01/10万剂(95%CI:0.00/10万剂~0.08/10万剂)。Spearman秩相关分析显示,AEFI与异常反应具有相关性(r=0.64,P=0.048),与死亡无相关性(r=-0.34,P=0.329),异常反应与死亡也无相关性(r=-0.25,P=0.484)。 结论: AEFI、异常反应与疑似预防接种有关的死亡均无相关性,偶合症为疑似预防接种有关死亡的主要原因。.

来源:Zhonghua Yu Fang Yi Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Xiao JX, Lin ZQ, Wu RH, et al. [Analysis on the characteristics of suspected vaccine-related deaths in Fujian Province, 2012-2017]. Zhonghua Yu Fang Yi Xue Za Zhi. 2019. PMID: 31288344. doi:10.3760/cma.j.issn.0253-9624.2019.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。